Latest news
Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication ‘Reinforce Our Confidence’ For Approval - StocktwitsStocktwits · Fri, 07 Aug 2026 01:26:29 GMTCapricor CEO won’t rule out legal action against FDA after negative adcomm - BioSpaceBioSpace · Fri, 31 Jul 2026 18:43:14 GMTFriday Five – Alnylam's quarter-cutting quarter, AstraZeneca's Claudin consolation, Capricor's statistical shock sequel…and more - FirstWord PHARMAFirstWord PHARMA · Fri, 31 Jul 2026 00:51:36 GMTCapricor plummets after FDA panel votes against Duchenne heart disease therapy - The Mighty 790 KFGOThe Mighty 790 KFGO · Thu, 30 Jul 2026 18:07:08 GMTFDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting - BioSpaceBioSpace · Wed, 29 Jul 2026 07:00:00 GMTFDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 07:00:00 GMTThis Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - TradingViewTradingView · Tue, 28 Jul 2026 16:07:59 GMTFDA scientists question Capricor data; Legend CEO steps down - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT